Literature DB >> 15703276

Characterization of the APP proximal promoter and 5'-untranslated regions: identification of cell type-specific domains and implications in APP gene expression and Alzheimer's disease.

Debomoy K Lahiri1, Yuan-Wen Ge, Bryan Maloney.   

Abstract

Alzheimer's disease is characterized by brain deposition of toxic amyloid beta-peptide (Abeta), generated from the Abeta precursor protein (APP). APP gene expression is regulated via the proximal promoter region (PPR; -46/-1 in the human sequence; +1 transcription start) and the 5'-untranslated region (5'-UTR; +1/+147). We have recently identified a unique CAGA sequence, "amyloid" (+83/+86) present only in the APP gene from amyloid plaque-forming species, absent in all APP-like-proteins' (APLP1 and APLP2) genes. To assay functional activity of PPR + UTR and 5'-UTR regions that either contain or lack the "amyloid" box, we tested nine constructs in transient transfection studies. We observed significantly high reporter gene activity with -46/144, -46/100, -46/54, and 54/144 constructs. The 54/100 fragment, which contains a transforming growth factor-beta/ "amyloid"/interleukin-1 acute box cassette, showed different activity depending on cell type. Electrophoretic mobility shift assay (EMSA) showed distinct DNA-nuclear protein interaction in all fragments, differing among both cell types and specific fragment. Reporter gene expression corroborates with the DNA-protein binding pattern. To directly examine the "amyloid" box, we generated oligomers for CAGA mutants or mutated adjacent nucleotides. EMSA results showed that altering "amyloid" or adjacent sequence alters specific DNA-nuclear protein interaction in both mutation- and cell-type-specific manners. Reporter gene assay reveals mutant-specific expression effects. Therefore, the -46/54 region appears to be essential for basal expression of the APP gene, the 54/100 and 100/144 regions may have tissue-specific activity, and the "amyloid" CAGA box plays a role in APP gene regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703276     DOI: 10.1096/fj.04-2900fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  20 in total

1.  Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells.

Authors:  Debomoy K Lahiri; Bryan Maloney; Yuan-Wen Ge
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2012-01-30       Impact factor: 3.688

3.  The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.

Authors:  Jack T Rogers; Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Deborah H Smith; Xudong Huang; Sanghamitra Bandyopadhyay; Catherine M Cahill; Maria L Maccecchini; Debomoy K Lahiri; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2011-01-08       Impact factor: 3.575

4.  A nuclear factor-binding domain in the 5'-untranslated region of the amyloid precursor protein promoter: implications for the regulation of gene expression.

Authors:  Alexander A Vostrov; Michael J Taheny; Nerik Izkhakov; Wolfgang W Quitschke
Journal:  BMC Res Notes       Date:  2010-01-12

5.  Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis.

Authors:  Jason A Bailey; Bryan Maloney; Yuan-Wen Ge; Debomoy K Lahiri
Journal:  Gene       Date:  2011-06-25       Impact factor: 3.688

6.  MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients.

Authors:  Justin M Long; Balmiki Ray; Debomoy K Lahiri
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 7.  Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders.

Authors:  Justin M Long; Debomoy K Lahiri
Journal:  Exp Neurol       Date:  2012-01-05       Impact factor: 5.330

8.  Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Authors:  Lynn M Bekris; Debby W Tsuang; Elaine R Peskind; Chang E Yu; Thomas J Montine; Jing Zhang; Cyrus P Zabetian; James B Leverenz
Journal:  Mov Disord       Date:  2015-03-24       Impact factor: 10.338

9.  Meta-analysis of the transforming growth factor-β1 polymorphisms and susceptibility to Alzheimer's disease.

Authors:  Wei-wei Chang; Liu Zhang; Yue-long Jin; Ying-shui Yao
Journal:  J Neural Transm (Vienna)       Date:  2012-07-11       Impact factor: 3.575

10.  eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer's disease.

Authors:  Andrew Bottley; Nicola M Phillips; Thomas E Webb; Anne E Willis; Keith A Spriggs
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.